Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-10-20 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
2024年半年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the implementation of the 2024 semi-annual dividend distribution. It details the dividend amount per share, relevant dates (record date, ex-dividend date, payment date), the authorization from the shareholders' meeting and board meeting, tax treatment for different shareholders, and instructions for dividend distribution. The document is focused on the dividend distribution plan and its implementation rather than presenting financial statements or comprehensive financial performance data. The document length is 3758 characters, which is relatively short and typical for a dividend announcement. Therefore, this document fits the category of Notice of Dividend Amount (DIV).
2024-10-20 Chinese
海通证券股份有限公司关于上海宣泰医药科技股份有限公司差异化分红事项的核查意见
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the company's 2024 semi-annual profit distribution involving a differentiated dividend policy due to treasury shares held in a repurchase account. It includes specifics about the board meetings, dividend amounts, share repurchase details, and legal compliance checks by the sponsor institution. The content focuses on dividend distribution, share repurchase, and related regulatory compliance rather than presenting a full financial report or earnings summary. The document length is 2293 characters, which is relatively short but contains substantive information about dividend distribution and share repurchase plans. This fits best under the category of Notice of Dividend Amount (DIV), as it announces the dividend amount, payment basis, and related shareholder information. It is not a full annual or interim report, nor a simple announcement of report publication. Therefore, the classification is DIV with high confidence.
2024-10-20 Chinese
关于实施2024年半年度权益分派后调整回购股份价格上限的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the adjustment of the upper limit of the share repurchase price following the 2024 semi-annual dividend distribution. It details the background, reasons, and calculation for adjusting the repurchase price limit, referencing previous announcements and regulatory compliance. The content focuses on share repurchase price adjustments and related corporate actions, not on financial results, earnings, or management reports. It is a formal disclosure about share repurchase price changes, which fits the category of a Transaction in Own Shares (POS) filing rather than a full financial report or dividend notice.
2024-10-20 Chinese
关于持股5%以上股东部分股份解除质押及质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the partial release and new pledging of shares held by a shareholder owning more than 5% of the company's shares. It details the number of shares pledged and released, the proportion of shares involved, and the relevant dates. The content focuses on share pledge and release activities, which are related to changes in shareholding and capital structure but do not constitute a full financial report or earnings release. The document length is 1761 characters, which is relatively short and typical for a share pledge announcement. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes including share pledges and releases.
2024-10-16 Chinese
关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the number of shares repurchased, the price range, the total amount spent, and references regulatory compliance with stock exchange rules. The document does not contain financial statements or detailed financial analysis but is a status update on the company's share buyback activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-10-08 Chinese
关于公司产品达格列净二甲双胍缓释片获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product by the national drug regulatory authority. It details the product's registration, approval status, and potential market impact. The document is short (1176 characters) and serves as a formal notification to shareholders and the public about a regulatory milestone rather than a financial report or detailed presentation. There is no financial data, no mention of annual or quarterly results, no management changes, no voting results, and no detailed investor presentation. It is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-09-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.